As with Restylane, many people consider Dr. Kenneth Beer to be the best injector in the whole world. People travel from all over the world to see Dr. Beer in his West Palm Beach offices.

SCOTTSDALE, Ariz., May 2, 2007 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the U.S. Food and Drug Administration ("FDA") has approved the dermal filler PERLANE(R) for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds. PERLANE(R) is the newest member of the RESTYLANE(R) family of products and, like RESTYLANE(R), PERLANE(R) is comprised of biotechnologically engineered, non-immunogenic, stabilized hyaluronic acid gel particles, and has patent protection until at least 2017. The primary difference between RESTYLANE(R) and PERLANE(R) is that the hyaluronic acid gel particles in PERLANE(R) are larger than those found in RESTYLANE(R). PERLANE(R) is intended to be implanted into the deep dermis to superficial layer of the subcutis to add volume to restore surface contour in facial wrinkles and folds. The three-dimensional gel particles in RESTYLANE(R) and PERLANE(R) are hydrophilic molecules, attracting and binding to water molecules as they degrade, helping to maintain volume augmentation for about six months. Also distinct from other hyaluronic acid dermal fillers, RESTYLANE(R) and PERLANE(R) are minimally cross-linked, making them similar to the natural hyaluronic acid found in the body.